Skip to main content
Premium Trial:

Request an Annual Quote

Viome, Helomics Form Microbiome Analysis Partnership

NEW YORK (GenomeWeb) — Viome announced today that it has partnered with Helomics to investigate the associations between ovarian cancer and the gut microbiome.

According to Seattle-based Viome, the partners are planning a pilot study that will examine the differences in the microbiomes of ovarian cancer patients versus healthy individuals, how different cancer therapies can alter the microbiome, and if microbiome composition influences cancer treatment efficacy and toxicity.

Viome — which offers direct-to-consumer microbiome testing to guide nutritional choices — said it aims to use data from the study to understand how nutrition may aid in the recovery of post-treatment ovarian cancer patients.

The study will apply Viome's artificial intelligence technology and sequencing-based microbiome analysis platform — which analyzes stool samples to determine the microbial composition of the gut — with Helomics' tumor profiling technology and D-Chip searchable bioinformatics platform for mining proprietary multi-omic and clinical data.

Additional terms of the deal were not disclosed.

"The collaboration with Viome is groundbreaking, generating data from the microbiome combined with our existing data and using our respective AI platforms, to offer an innovative, holistic, and personalized approach to helping oncologists choose the best treatment options for patients with ovarian cancer," Helomics President and CEO Gerald Vardzel said in a statement.

In mid-2018, Precision Therapeutics signed an agreement to acquire the 75 percent of Pittsburgh-based Helomics that it does not already own. Precision shareholders are slated to vote on the transaction this month.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.